Market Survey on Antisense Oligonucleotides Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Antisense Oligonucleotides Market including Approved Drugs, Pegaptanib, Mipomersen, Eteplirsen, and Pipeline Analysis Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
The global antisense oligonucleotides market is projected to amass revenue of around US$ 5,519.6 million by 2033, up from US$ 2,913.5 million in 2023 moving forward with a CAGR of 6.6% during the forecast period.
The antisense oligonucleotides adoption trends are significantly swayed by their promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets that cannot be treated with protein therapeutics, propelling the market growth. They target a particular malfunctioning gene, interfere with RNA function at the cellular level, and also be silenced or modulated and the same is catching the attention of market players.
The rising demand for antisense oligonucleotides is attributed to its aid in modifying the immune system that facilitates the treatment of a wide range of autoimmune disorders - that cannot be treated with available drugs.
It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.
Moreover, the market is enhanced by the minimal side effects of antisense oligonucleotides, which are controlled with ease as compared to other classes of drugs.
The antisense oligonucleotides sector has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 - which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).
However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.
However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes of infant mortality with no approved treatments.
Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the market outlook is positively influenced by the leading players in the market and the amount of research and development investments.
Attributes
Details
Antisense Oligonucleotides Market CAGR (2023 to 2033)
6.6%
Antisense Oligonucleotides Market Size (2023)
US$ 2,913.5 million
Antisense Oligonucleotides Market Size (2033)
US$ 5,519.6 million
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What Factors are Shaping the Antisense Oligonucleotides Industry?
A strong pipeline of antisense oligonucleotides and increased focus on a large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides sector size.
Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level are further contributing to the growth of the global market.
However, the global antisense oligonucleotides business is grappling with numerous challenges related to the diversity of oligonucleotides, delivery, and regulatory complexity.
Despite several advancements at clinical levels, the delivery of active oligonucleotides to the actual site within target cells is still one of the key challenges hindering the growth of the global antisense oligonucleotides sector. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the market statistics.
Comparative View of the Market
Antisense Oligonucleotides Market:
Attributes
Antisense Oligonucleotides Market
CAGR (2023 to 2033)
6.6%
Market Value (2033)
US$ 5,519.6 million
Growth Factor
Promising treatment offers for medical disorders
Opportunity
Rising number of FDA approval
Trends
Advanced pharmacological techniques
Oligonucleotides Market:
Attributes
Oligonucleotides Market
CAGR (2023 to 2033)
5.3%
Market Value (2033)
US$ 11,930 million
Growth Factor
Widespread use in various ailments
Opportunity
Technology advancement in pharmaceutical
Trends
Rising demand for personalized treatment
Fructo-oligosaccharides Market:
Attributes
Fructo-oligosaccharides Market
CAGR (2023 to 2033)
6%
Market Value (2033)
US$ 4,919.5 million
Growth Factor
Surging awareness about health awareness
Opportunity
Growing research work to maintain digestive system
Find your sweet spots for generating winning opportunities in this market.
Regional Analysis
Countries
Market Share (2022)
United States
58%
Germany
3.3%
Japan
2.9%
Why is North America Expected to Dominate the Antisense Oligonucleotides Industry?
North America clearly dominates the global antisense oligonucleotides industry due to a strong product pipeline and an increasing number of FDA approvals in the region, contributing to the region’s market share of 60.9% in 2022.
For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the USA in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.
What are the Growth Prospects for the Europe Antisense Oligonucleotides Business?
In 2022, the Europe antisense oligonucleotides sector captured a share of 14.3%. In order to improve their product portfolio for antisense oligonucleotides, key players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the market growth in Europe.
For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market growth to some level.
How is the Start-up Ecosystem in the Antisense Oligonucleotides Industry?
While many organizations are working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are also emerging, shaping the market trends.
Examples:
RNA-targeting biopharmaceuticals are being created by the USA-based start-up Arrakis Therapeutics.
The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.
These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.
Antisense RNA therapies are created by the Spanish start-up ARTHEx Biotech for hereditary illnesses.
The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
How Strong Is the Competition in the Antisense Oligonucleotides Business?
The market for antisense oligonucleotides is fairly consolidated, with a few competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.
A couple of recent developments are:
AmpTec, a renowned German company that specializes in mRNA contract development and manufacture, was purchased by MilliporeSigma (USA) (CDMO).
The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.
oPools- oligo pools, a collection of 350-nucleotide-long, high-quality DNA oligonucleotides, was introduced by Integrated DNA Technology (USA).
Key player
Ionis Pharmaceuticals, Inc.
Sarepta Therapeutics
Biogen
Alnylam Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Isarna Therapeutics GmbH
Arrowhead Pharmaceuticals, Inc.
Atlantic Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
Gene Signal International SA
GlaxoSmithKline plc
Geron Corporation
Grades
ICO Therapeutics
Aptose Biosciences
Marina Biotech
miRagen Therapeutics, Inc.
Synlogic, Inc.
OncoGenex Pharmaceuticals Inc.
Pharmaxis Ltd, Regulus Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
RXi Pharmaceuticals
Key Segments
By Drug:
Approved Drugs
Pegaptanib
Mipomersen
Eteplirsen
Pipeline Analysis
By Indication:
Ocular Diseases
Cancer
Diabetes
Amyotrophic Lateral Sclerosis (ALS)
Duchenne Muscular Dystrophy
Spinal Muscular Atrophy
Others
By Application:
Basic Research
Genomics
Target Validation
Drug Discovery
By Region:
North America
Latin America
Asia Pacific
The Middle East and Africa
Europe
Frequently Asked Questions
Why is North America Emerging as an Opportunistic Market?
Robust product pipeline and rising FDA approvals in the region dominate the market.
What is the Lucrative Opportunity in the Market?
The rising number of FDA approvals is the key opportunity in the market.
What is the Key Trend of the Market?
Advanced pharmacological techniques are the key trend.
What Drives Sales of the Market?
Promising treatment offers for medical disorders.
What is the Growth Forecast for the Market?
The market is forecast to register a CAGR of 6.6% through 2033.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
5.3.1. Approved Drugs
5.3.2. Pegaptanib
5.3.3. Mipomersen
5.3.4. Eteplirsen
5.3.5. Pipeline Analysis
5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
6.3.1. Ocular Diseases
6.3.2. Cancer
6.3.3. Diabetes
6.3.4. Amyotrophic Lateral Sclerosis (ALS)
6.3.5. Duchenne Muscular Dystrophy
6.3.6. Spinal Muscular Atrophy
6.3.7. Others
6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application , 2023 to 2033
7.3.1. Basic Research
7.3.2. Genomics
7.3.3. Target Validation
7.3.4. Drug Discovery
7.4. Y-o-Y Growth Trend Analysis By Application , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Application , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA.
9.2.1.2. Canada
9.2.2. By Drug
9.2.3. By Indication
9.2.4. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug
9.3.3. By Indication
9.3.4. By Application
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug
10.2.3. By Indication
10.2.4. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug
10.3.3. By Indication
10.3.4. By Application
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Drug
11.2.3. By Indication
11.2.4. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug
11.3.3. By Indication
11.3.4. By Application
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Drug
12.2.3. By Indication
12.2.4. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug
12.3.3. By Indication
12.3.4. By Application
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Drug
13.2.3. By Indication
13.2.4. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug
13.3.3. By Indication
13.3.4. By Application
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug
14.2.3. By Indication
14.2.4. By Application
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug
14.3.3. By Indication
14.3.4. By Application
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug
15.2.3. By Indication
15.2.4. By Application
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug
15.3.3. By Indication
15.3.4. By Application
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug
16.1.2.2. By Indication
16.1.2.3. By Application
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug
16.2.2.2. By Indication
16.2.2.3. By Application
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug
16.3.2.2. By Indication
16.3.2.3. By Application
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug
16.4.2.2. By Indication
16.4.2.3. By Application
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug
16.5.2.2. By Indication
16.5.2.3. By Application
16.6. United Kingdom.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug
16.6.2.2. By Indication
16.6.2.3. By Application
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug
16.7.2.2. By Indication
16.7.2.3. By Application
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug
16.8.2.2. By Indication
16.8.2.3. By Application
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug
16.9.2.2. By Indication
16.9.2.3. By Application
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug
16.10.2.2. By Indication
16.10.2.3. By Application
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug
16.11.2.2. By Indication
16.11.2.3. By Application
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug
16.12.2.2. By Indication
16.12.2.3. By Application
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug
16.13.2.2. By Indication
16.13.2.3. By Application
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug
16.14.2.2. By Indication
16.14.2.3. By Application
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug
16.15.2.2. By Indication
16.15.2.3. By Application
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug
16.16.2.2. By Indication
16.16.2.3. By Application
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug
16.17.2.2. By Indication
16.17.2.3. By Application
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug
16.18.2.2. By Indication
16.18.2.3. By Application
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug
16.19.2.2. By Indication
16.19.2.3. By Application
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug
16.20.2.2. By Indication
16.20.2.3. By Application
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug
16.21.2.2. By Indication
16.21.2.3. By Application
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Drug
16.22.2.2. By Indication
16.22.2.3. By Application
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Drug
16.23.2.2. By Indication
16.23.2.3. By Application
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug
17.3.3. By Indication
17.3.4. By Application
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Ionis Pharmaceuticals, Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Sarepta Therapeutics
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Biogen
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Alnylam Pharmaceuticals, Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Antisense Therapeutics Limited
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Isarna Therapeutics GmbH
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Arrowhead Pharmaceuticals, Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Alantic Pharmaceuticals, Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Enzon Pharmaceuticals, Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Bio-Path Holdings, Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Gene Signal International SA
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. GlaxoSmithKline plc
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.13. Geron Corporation
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
18.1.14. Grades
18.1.14.1. Overview
18.1.14.2. Product Portfolio
18.1.14.3. Profitability by Market Segments
18.1.14.4. Sales Footprint
18.1.14.5. Strategy Overview
18.1.14.5.1. Marketing Strategy
18.1.15. ICO Therapeutics
18.1.15.1. Overview
18.1.15.2. Product Portfolio
18.1.15.3. Profitability by Market Segments
18.1.15.4. Sales Footprint
18.1.15.5. Strategy Overview
18.1.15.5.1. Marketing Strategy
18.1.16. Aptose Biosciences
18.1.16.1. Overview
18.1.16.2. Product Portfolio
18.1.16.3. Profitability by Market Segments
18.1.16.4. Sales Footprint
18.1.16.5. Strategy Overview
18.1.16.5.1. Marketing Strategy
18.1.17. Marina Biotech
18.1.17.1. Overview
18.1.17.2. Product Portfolio
18.1.17.3. Profitability by Market Segments
18.1.17.4. Sales Footprint
18.1.17.5. Strategy Overview
18.1.17.5.1. Marketing Strategy
18.1.18. miRagen Therapeutics, Inc.
18.1.18.1. Overview
18.1.18.2. Product Portfolio
18.1.18.3. Profitability by Market Segments
18.1.18.4. Sales Footprint
18.1.18.5. Strategy Overview
18.1.18.5.1. Marketing Strategy
18.1.19. Synlogic, Inc.
18.1.19.1. Overview
18.1.19.2. Product Portfolio
18.1.19.3. Profitability by Market Segments
18.1.19.4. Sales Footprint
18.1.19.5. Strategy Overview
18.1.19.5.1. Marketing Strategy
18.1.20. OncoGenex Pharmaceuticals Inc.
18.1.20.1. Overview
18.1.20.2. Product Portfolio
18.1.20.3. Profitability by Market Segments
18.1.20.4. Sales Footprint
18.1.20.5. Strategy Overview
18.1.20.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Application , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Indication, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Application , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 17: Global Market Attractiveness by Drug, 2023 to 2033
Figure 18: Global Market Attractiveness by Indication, 2023 to 2033
Figure 19: Global Market Attractiveness by Application , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Application , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 37: North America Market Attractiveness by Drug, 2023 to 2033
Figure 38: North America Market Attractiveness by Indication, 2023 to 2033
Figure 39: North America Market Attractiveness by Application , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Application , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Indication, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Application , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Indication, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by Application , 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Drug, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Indication, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by Application , 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Indication, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by Application , 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Drug, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Indication, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by Application , 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia and Pacific Market Value (US$ Million) by Drug, 2023 to 2033
Figure 102: South Asia and Pacific Market Value (US$ Million) by Indication, 2023 to 2033
Figure 103: South Asia and Pacific Market Value (US$ Million) by Application , 2023 to 2033
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 117: South Asia and Pacific Market Attractiveness by Drug, 2023 to 2033
Figure 118: South Asia and Pacific Market Attractiveness by Indication, 2023 to 2033
Figure 119: South Asia and Pacific Market Attractiveness by Application , 2023 to 2033
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 121: East Asia Market Value (US$ Million) by Drug, 2023 to 2033
Figure 122: East Asia Market Value (US$ Million) by Indication, 2023 to 2033
Figure 123: East Asia Market Value (US$ Million) by Application , 2023 to 2033
Figure 124: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 137: East Asia Market Attractiveness by Drug, 2023 to 2033
Figure 138: East Asia Market Attractiveness by Indication, 2023 to 2033
Figure 139: East Asia Market Attractiveness by Application , 2023 to 2033
Figure 140: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 141: Middle East and Africa Market Value (US$ Million) by Drug, 2023 to 2033
Figure 142: Middle East and Africa Market Value (US$ Million) by Indication, 2023 to 2033
Figure 143: Middle East and Africa Market Value (US$ Million) by Application , 2023 to 2033
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 157: Middle East and Africa Market Attractiveness by Drug, 2023 to 2033
Figure 158: Middle East and Africa Market Attractiveness by Indication, 2023 to 2033
Figure 159: Middle East and Africa Market Attractiveness by Application , 2023 to 2033
Figure 160: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
